Campbell Hutton

[Breakthrough T1D @BreakthroughT1D]

Breakthrough T1D (formerly JDRF) has a clear mission: accelerate life-changing breakthroughs to cure, prevent, and treat type 1 diabetes (T1D), and its complications. We have a clear vision of how to achieve that mission: our cures strategy, which includes cell therapies.

Project Accelerate Cell Therapies, or Project ACT, is our game plan to make cell therapies a reality for millions around the world who live with #T1D.

To learn more, visit https://t.co/igcBvO76XP

[U.S. FDA @FDA]

Today, we approved a first-in-class injection to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes. https://t.co/6gid70MJAd

[Breakthrough T1D @BreakthroughT1D]

JDRF celebrates today’s decision from the U.S. Food and Drug Administration (FDA) to approve teplizumab (under the brand name Tzield) for use in delaying type 1 diabetes (T1D) in at-risk individuals. This is a huge step on the path towards our vision of a world without T1D. (1/2)

[Aaron Turner-Phifer @turner_phifer]

Honored to represent @JDRFAdvocacy at the White House today! Great to hear firsthand from long-time T1D advocate Bob Parant about the impact of lower insulin costs!

[Breakthrough T1D @BreakthroughT1D]

We are thrilled to announce that JDRF is supporting Civica's newly established program to develop affordable insulin. Civica is a nonprofit generic drug manufacturing company founded by leading health systems. (1/3)

[Breakthrough T1D @BreakthroughT1D]

JDRF is glad President Biden used the State of the Union to address the insulin affordability crisis, which has had devastating consequences in the diabetes community for far too long. (1/3)

[Breakthrough T1D Advocacy @BT1D_Advocacy]

JDRF is glad President Biden used the State of the Union to address the insulin affordability crisis, which has had devastating consequences in the diabetes community for far too long.

[JDRF Research @JDRFResearch]

Great update from @EMA_News, which presented a letter of support to the @CPathInstitute T1D Consortium (which includes @JDRF) to facilitate the development and validation of autoantibodies for T1D for regulatory use.

Learn more https://t.co/SVO9N32CJG.

[Breakthrough T1D Advocacy @BT1D_Advocacy]

Thank you, Members of the U.S. Senate, for prioritizing #T1D research by advancing $12 mil in Special Diabetes Program (SDP) funding, through December 20. This funding allows critical research to continue that is unlocking results moving us closer to cures. #RenewSDP

[Breakthrough T1D Advocacy @BT1D_Advocacy]

Ask your Senators TODAY to support their constituents w/ #T1D by signing the Special Diabetes Program (SDP) letter. If you live in ID, MA, MD, ME, MI, MN, MS, ND, NM, NV, OR, RI, SD, or VT, both your Senators have signed! Everyone else, act NOW: https://t.co/S5m7oAphij #RenewSDP

[Taylor Elementary @APSTaylor]

The bunny came back to school today and is checking books out of @TaylorESLibroar #cute @TaylorPTAtalk @ilovearlingtonv @i_love_books @APSLibrarians @APSVaSchoolBd @APSVirginia @ILAToday

[CDC @CDCgov]

Pregnant women are 5 times more likely to develop a #bloodclot compared to women who are not pregnant. Learn more about pregnancy-related blood clots. https://t.co/jmz2bzRGPl

[Breakthrough T1D @BreakthroughT1D]

Breaking news! @LillyDiabetes announces a generic version of Humalog available at 50% lower list price.

[Breakthrough T1D @BreakthroughT1D]

From now until April 27th when you shop at your local @HarrisTeeter you’ll have the chance to join them in supporting cutting-edge type 1 diabetes (T1D) research! Need help finding your closest store? Visit the link below!

https://t.co/MbrGPNxVhT

[HHS @HHSGov]

The @US_FDA has authorized the first insulin pump that can communicate with other diabetes management devices, allow patients to customize treatment: https://t.co/zvfRt4FT7W

[FDA Medical Devices @FDADevices]

#ICYMI: FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices. Read more here: https://t.co/m9Ie7RigUc #MedicalDevice #FDA

[Breakthrough T1D Advocacy @BT1D_Advocacy]

Last year, the Dexcom G6 continuous glucose monitor system was cleared as the first iCGM, and @JDRF is currently funding @Tidepool_org to develop the first FDA-regulated #insulin delivery app: https://t.co/hpLqvWnZLr

[Taylor Elementary @APSTaylor]

More animal prints & patterns #FunFriday !! @APSVirginia @TaylorPTAtalk @ztaylorfifth @ZTcreates

[Taylor Elementary @APSTaylor]

Stitch, #RaggedyAnn , a Minion & @thecatinthehat4 came to visit us today. @TaylorPTAtalk @APSVirginia @BenchmarkEdu @DrSeuss @ilovearlingtonv